HIT:NSD-Health In Tech, Inc. Class A Common Stock (USD)

COMMON STOCK | Scientific & Technical Instruments |

Last Closing

USD 5.5

Change

+0.40 (+7.84)%

Market Cap

N/A

Volume

0.32M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Scientific & Technical Instruments

Symbol Name Price(Change) Market Cap
TRMB Trimble Inc

+0.70 (+0.98%)

USD 18.06B
MKSI MKS Instruments Inc

+1.29 (+1.21%)

USD 7.62B
CGNX Cognex Corporation

+0.54 (+1.49%)

USD 6.43B
NOVT Novanta Inc

+1.74 (+1.13%)

USD 5.97B
ITRI Itron Inc

+1.52 (+1.40%)

USD 5.15B
MLAB Mesa Laboratories Inc

-4.15 (-3.06%)

USD 0.67B
ITRN Ituran Location and Control Lt..

+0.88 (+2.97%)

USD 0.61B
FARO FARO Technologies Inc

+0.31 (+1.22%)

USD 0.52B
MVIS Microvision Inc

+0.01 (+0.91%)

USD 0.20B
SOTK Sono-Tek Corp

-0.07 (-1.72%)

USD 0.08B

ETFs Containing HIT

N/A

Market Performance

  Market Performance vs. Industry/Classification (Scientific & Technical Instruments) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike